

Discussions with leaders: *JNM* editor-in-chief Johannes Czernin continues a series of interviews with leaders in nuclear and molecular imaging and therapy, talking with David Townsend, PhD, and Thomas Beyer, PhD, MBA, about their pioneering work in development of PET/CT technology. **Page 1541**

Improving TRT approaches: Chan and colleagues present a state-of-the-art review of combination strategies with targeted radionuclide therapy as reported in the literature and describe the associated therapeutic potential. **Page 1544**

Imaging the cancer immune environment: Iravani and Hicks continue an educational overview of immune environment oncologic monitoring with PET, looking beyond ¹⁸F-FDG PET to novel agents and suggesting an algorithm for evaluation and integration into routine practice. **Page 1553**

¹⁸F-FDG PET/CT and PRRT prognosis: Zhang and colleagues report on the predictive role of ¹⁸F-FDG PET/CT in a large cohort of patients with metastatic neuroendocrine neoplasms treated with peptide-receptor radionuclide therapy, including long-term follow-up. **Page 1560**

Total-lesion volume and glycolysis: Reynolds and colleagues explore the implications of tumor metabolic and volume metrics as assessed on ¹⁸F-FDG PET in patients with malignant pleural mesothelioma. **Page 1570**

⁶⁸Ga-PSMA-11 for colorectal cancer: Cuda and colleagues image patients with metastatic colorectal cancer to assess the tumor avidity of this prostate-specific membrane antigen-targeting agent to inform decision making in peptide-receptor radionuclide therapy. **Page 1576**

First-in-humans trial of ¹⁸F-SKI-249380: Krebs and colleagues detail the results of whole-body PET/CT imaging with this dasatinib-derivative imaging agent in patients with prior diagnoses of breast cancer, renal cell cancer, or leukemia. **Page 1580**

PDT of GLP-1R-positive lesions: Boss and colleagues describe a novel method for therapy of hyperinsulinemic hypoglycemia,

selectively killing β -cells by receptor-targeted photodynamic therapy with exendin-4-IRDye 700DX, targeting the glucagonlike peptide 1 receptor. **Page 1588**

⁸⁹Zr-BiTE molecules: Suurs and colleagues explore the pharmacokinetic characteristics and immune cell roles of radiolabeled bispecific T-cell engager molecules in immunocompetent and immunodeficient mouse models. **Page 1594**

Neuroendocrine differentiation and RLT: Derlin and colleagues investigate the effect of circulating neuroendocrine biomarkers on the efficacy of prostate-specific membrane antigen-targeted radioligand therapy. **Page 1602**

⁶⁸Ga-PSMA-guided bone biopsies: de Jong and colleagues determine the success rate of ⁶⁸Ga-prostate-specific membrane antigen-guided bone biopsies for molecular diagnostics in patients with metastatic prostate cancer. **Page 1607**

Partial-volume effect on PSMA uptake: Ortega and colleagues research the effect of a smoothing filter and partial-volume correction on ¹⁸F-DCFPyL PET/CT-measured prostate-specific membrane antigen activity in small metastatic lesions and resulting changes on PSMA molecular imaging scoring. **Page 1615**

TSPO radioligand data pooling in ALS: Van Weehaeghe and colleagues ask whether data pooling of different translocator protein radioligands is feasible for use in multicenter pharmacodynamic biomarker analyses in amyotrophic lateral sclerosis trials. **Page 1621**

Quantification of ¹²³FP-CIT SPECT in DLB: Maltais and colleagues describe the results of a retrospective study comparing 3 ¹²³FP-CIT SPECT quantitative methods in patients with neurodegenerative syndromes and compare with neuropathologic findings. **Page 1628**

Kinetic analysis of novel κ -agonists: Naganawa and colleagues assess in humans the kinetics, binding properties, and test-retest reproducibility of 2 ¹¹C-labeled κ -opioid receptor agonist radiotracers for PET imaging. **Page 1636**

Folate receptor imaging in myocarditis: Jahandideh and colleagues evaluate ¹⁸F-FOL PET for detection of myocardial inflammation in rats with autoimmune myocarditis and study the expression of folate receptor β in human cardiac sarcoidosis specimens. **Page 1643**

Lung ABCB1 activity: Mairinger and colleagues detail preclinical studies of PET imaging with pulmonary-administered ¹¹C-BMP to measure multidrug resistance-associated protein ABCB1 activity at the lung epithelial barrier and describe potential clinical applications. **Page 1650**

Radiobiological dosimetry for SIRT: Abbott and colleagues report on establishment of dose-response relationships for selective internal radiation therapy in patients with metastatic colorectal cancer when informed by radiobiologic sensitivity parameters derived from mCRC cell lines exposed to ⁹⁰Y. **Page 1658**

¹¹C-PABA PET renal imaging: Ruiz-Bedoya and colleagues explore in both preclinical and first-in-humans studies the hypothesis that ¹¹C-labeled *para*-aminobenzoic acid may allow high-quality dynamic PET of the kidneys with less radiation exposure. **Page 1665**

Phosphodiesterase type 4 PET in MAS: Weidner and colleagues investigate the potential of PET imaging with ¹¹C-(R)-rolipram to indirectly measure and elucidate the mechanisms of increased 3',5'-cyclic adenosine monophosphate pathway activation in patients with McCune-Albright syndrome. **Page 1672**

Data- versus device-based gating: Walker and colleagues compare the performance of a recently commercialized data-driven method for respiratory gating with that of an external, device-based system for oncologic ¹⁸F-FDG PET/CT imaging. **Page 1678**

Lesion detectability with digital PET: Surti and colleagues report on a lesion detectability investigation of 2 generations of Biograph PET/CT scanners, the mCT Flow and the Vision, to study the impact of improved physical performance on clinical performance. **Page 1684**